For ten years the FDA's 2014 black box warning shaped how every primary care doctor thought about testosterone therapy. The TRAVERSE trial in 2023 and the FDA's 2025 label revision started turning the tide. On February 11, 2026, the International Journal of Impotence Research published a meta-analysis that pulled together every randomized controlled trial of TRT and prostate or cardiovascular outcomes — 41 trials, 11,161 men — and the picture sharpened again.
The headline: testosterone therapy did not raise the rate of heart attacks, strokes, or prostate cancer in pooled randomized data.
Key Takeaways
- 41 randomized controlled trials, 11,161 men, registered in PROSPERO
- Major adverse cardiovascular events: OR 0.83 (95% CI: 0.52-1.32) — no harm signal
- Any prostate cancer: OR 0.88 (95% CI: 0.52-1.51) — no harm signal
- Clinically significant prostate cancer: OR 1.13 (95% CI: 0.39-3.26) — wide interval, no signal
- Authors conclude: short- to mid-term safety supported, long-term data still needed
- Reinforces the TRAVERSE finding and supports the FDA's 2025 label changes
What the Authors Did
This was a PRISMA-compliant systematic review and meta-analysis, registered prospectively in PROSPERO (CRD42024603054). The authors searched databases for randomized controlled trials comparing testosterone replacement therapy against placebo or no treatment in men with hypogonadism. They screened 3,794 records and pulled the 41 trials that met inclusion criteria.
Pooled Cohort Snapshot
| Parameter |
Detail |
| Trials included |
41 RCTs |
| Total participants |
11,161 men |
| Outcomes pooled |
MACE, any prostate cancer, clinically significant prostate cancer |
| Registration |
PROSPERO CRD42024603054 |
| Reporting standard |
PRISMA |
| Journal |
International Journal of Impotence Research |
| Publication date |
February 11, 2026 |
The three primary outcomes were chosen carefully. Major adverse cardiovascular events (MACE) is the composite that includes nonfatal heart attack, nonfatal stroke, and cardiovascular death — the same endpoint used in TRAVERSE. Any prostate cancer event captures everything from low-grade incidental findings on screening biopsies to aggressive disease. Clinically significant prostate cancer separates out Gleason 7 or higher — the disease that actually changes how long you live.
That third endpoint matters. Earlier meta-analyses lumped all prostate cancers together, which made low-grade indolent cancers (which often never progress) inflate the apparent harm. By pre-specifying clinically significant cancer as a separate outcome, this analysis answered the question men actually care about: does TRT cause the kind of prostate cancer that kills you?
What the Numbers Show
Three pooled odds ratios. None statistically significant. All point toward no detectable harm.
Cardiovascular Events
| Outcome |
Odds Ratio |
95% CI |
Interpretation |
| MACE (heart attack, stroke, CV death) |
0.83 |
0.52-1.32 |
No harm signal; trend toward fewer events |
An odds ratio of 0.83 means the TRT group had roughly 17% lower odds of a major cardiovascular event than the placebo group. The confidence interval crosses 1.0, so this is not a statistically significant protective effect — but it absolutely is not a signal of harm.
This matters historically. The 2014 FDA black box warning was driven largely by two retrospective database studies (Vigen 2013 and Finkle 2014) that suggested testosterone might raise heart attack risk. Both have since been heavily critiqued for confounding. The randomized data pooled here goes the other direction.
For the deeper history of the cardiovascular risk debate, see TRT and heart risk: TRAVERSE trial explained.
Prostate Cancer
| Outcome |
Odds Ratio |
95% CI |
Interpretation |
| Any prostate cancer |
0.88 |
0.52-1.51 |
No harm signal |
| Clinically significant cancer (Gleason ≥7) |
1.13 |
0.39-3.26 |
No harm signal; wide interval |
The any-prostate-cancer point estimate (0.88) is below 1.0 — meaning numerically fewer cancers in the TRT arm. The clinically significant prostate cancer point estimate (1.13) is above 1.0 but the confidence interval is huge (0.39 to 3.26), which means the analysis was statistically underpowered for this rarer outcome. The honest read is "no detectable signal" rather than "definitely no risk."
Either way, the old saturation-model concern — that giving testosterone to men with low T would feed dormant prostate cancers and unmask aggressive disease — does not show up in this pooled randomized data. For more on why that biological model was wrong, see testosterone and prostate cancer: separating fact from myth and the active surveillance prostate cancer study.
How This Stacks With Other 2026 Evidence
This meta-analysis does not exist in a vacuum. It sits on top of a stack of 2025 and 2026 papers that all point the same direction.
| Study |
Year |
n |
Headline Finding |
| TRAVERSE (NEJM) |
2023 |
5,246 |
No increase in MACE or prostate cancer |
| FDA Label Update |
2025 |
— |
Black box softened, expanded indications considered |
| Clift-Morgentaler real-world cohort |
2026 |
9,537 |
Hematocrit risk real, no MACE signal in observational data |
| This meta-analysis (IJIR) |
2026 |
11,161 |
Pooled RCTs: no MACE, no prostate cancer signal |
| FDA low-libido pathway |
2026 |
— |
Formal indication expansion underway |
The convergence is what makes the 2026 picture different from the 2014 picture. One trial (even one as big as TRAVERSE) can be dismissed as an outlier. A meta-analysis of 41 RCTs plus a 9,537-man real-world cohort plus an FDA policy reversal is a different category of evidence.
For the regulatory backdrop, see FDA testosterone descheduling and expanded access and FDA opens TRT pathway for low libido in men.
What This Does and Does Not Change
What It Changes
The default conversation with primary care. A patient asking about TRT can now point to this meta-analysis when a doctor cites 2014-era cardiovascular concerns. The randomized evidence does not support that fear.
The risk framing for men with stable CV disease. TRAVERSE specifically enrolled men at elevated cardiovascular risk and found no harm. This meta-analysis confirms the same in a broader population. Men with controlled hypertension, well-managed diabetes, or stable coronary disease do not have a clear contraindication based on TRT itself.
The prostate cancer screening conversation. TRT is no longer reasonably described as "feeding" prostate cancer. PSA monitoring is still the standard, but the framing has shifted from "TRT might cause cancer" to "TRT does not appear to cause cancer, but we monitor anyway because prostate cancer is common in this age group."
What It Does Not Change
Hematocrit monitoring is still the safety priority. The 9,537-man real-world cohort showed 24% of men cross the 0.54 L/L threshold within 12 months on TRT. That has not gone away. CBC at baseline, 6-8 weeks, 3 months, 6 months, and annually is non-negotiable.
Long-term cancer outcomes still need years. Most of the trials in this pool ran 3 to 36 months. Prostate cancer often takes 10 to 20 years to develop clinically. RCTs cannot answer the very-long-term question — only large registry studies with multi-decade follow-up can.
Men with active prostate cancer are still excluded. The "active surveillance" data is more permissive than older guidance, but men with untreated intermediate or high-risk prostate cancer were not included in these trials. Decisions in that population remain individualized.
Side effect monitoring is unchanged. Estradiol, lipids, sleep apnea, fertility, mood — none of these were endpoints in the pooled MACE-and-cancer analysis. Standard monitoring still applies. See TRT bloodwork schedule for the full cadence.
How Clinics Should Be Reading This
Three questions to ask any TRT provider in light of the new meta-analysis.
1. Do You Still Use 2014-Era Cardiovascular Talking Points?
Some clinics still front-load TRT consultations with heavy cardiovascular warnings drawn from the 2014 black box era. That language is now meaningfully out of step with 2026 evidence. A clinic that has updated its informed consent process to reflect TRAVERSE and the new meta-analysis is paying attention. One that hasn't is not.
2. What Is Your PSA Monitoring Protocol?
Despite the reassuring cancer data, PSA monitoring is still standard of care. Baseline PSA, repeat at 3-6 months, then annually. Any rise of more than 1.4 ng/mL in 12 months — or any rise above 4.0 — should prompt a urology referral. A clinic with no formal PSA escalation protocol is taking shortcuts.
3. Do You Treat Men With Stable Cardiovascular Disease?
The new evidence supports treating hypogonadal men with controlled CV disease who would benefit symptomatically from TRT. A clinic that reflexively turns away anyone with a history of MI, controlled hypertension, or stable CAD may be operating on outdated risk assumptions. A clinic that thoughtfully reviews CV history and individualizes the decision is current.
For our independent ratings of TRT providers on monitoring, transparency, and protocol quality, see Best online TRT clinics 2026. For the full clinic-vetting workflow, see how to choose a TRT clinic and questions to ask a TRT clinic.
Bottom Line
The 2026 IJIR meta-analysis is the most rigorous pooled analysis to date on the two safety questions that have shaped TRT prescribing for a decade. The answers — no significant signal for major cardiovascular events, no significant signal for prostate cancer of any grade — are unlikely to be overturned by a future trial in the same time horizon.
That does not make TRT risk-free. Hematocrit, fertility, estradiol, and individual response are still real. But the cardiovascular and prostate cancer story has tightened to the point where the burden of proof now sits with anyone claiming those harms exist in randomized data.
If you have been holding off on TRT because of an old black-box-era conversation with a doctor, this is the paper to bring to your next appointment.
References
- Cardiovascular and prostate cancer risk associated to testosterone replacement therapy — a systematic review and meta-analysis of 41 randomized controlled trials. International Journal of Impotence Research. Published February 11, 2026. DOI: 10.1038/s41443-026-01237-4.
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). N Engl J Med. 2023;389:107-117.
- U.S. Food and Drug Administration. FDA Takes Step Forward on Testosterone Therapy for Men. Press announcement, April 16, 2026.
- Clift AK, Johnson H, Huang DR, Morgentaler A. Real-World Outcomes and Safety of Testosterone Therapy: A Longitudinal, Retrospective Cohort Study of Over 9,000 Men. World Journal of Men's Health. 2026. DOI: 10.5534/wjmh.250245.
- Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-1836.
- Corona G, Rastrelli G, Di Pasquale G, et al. Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies. J Sex Med. 2018;15(6):820-838.
Related Reading